These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

132 related items for PubMed ID: 38086524

  • 1. Extended Treatment With Recombinant Human Parathyroid Hormone (1-84) in Adult Patients With Chronic Hypoparathyroidism.
    Rubin MR, Cusano N, Yin S, Tokareva E, Ayodele O, Finkelman RD.
    Endocr Pract; 2024 Mar; 30(3):200-208. PubMed ID: 38086524
    [Abstract] [Full Text] [Related]

  • 2. AN OPEN-LABEL EXTENSION STUDY OF PARATHYROID HORMONE RHPTH(1-84) IN ADULTS WITH HYPOPARATHYROIDISM.
    Lakatos P, Bajnok L, Lagast H, Valkusz Z.
    Endocr Pract; 2016 May; 22(5):523-32. PubMed ID: 26684150
    [Abstract] [Full Text] [Related]

  • 3. Efficacy and safety of recombinant human parathyroid hormone (1-84) in hypoparathyroidism (REPLACE): a double-blind, placebo-controlled, randomised, phase 3 study.
    Mannstadt M, Clarke BL, Vokes T, Brandi ML, Ranganath L, Fraser WD, Lakatos P, Bajnok L, Garceau R, Mosekilde L, Lagast H, Shoback D, Bilezikian JP.
    Lancet Diabetes Endocrinol; 2013 Dec; 1(4):275-83. PubMed ID: 24622413
    [Abstract] [Full Text] [Related]

  • 4. Effects of parathyroid hormone rhPTH(1-84) on phosphate homeostasis and vitamin D metabolism in hypoparathyroidism: REPLACE phase 3 study.
    Clarke BL, Vokes TJ, Bilezikian JP, Shoback DM, Lagast H, Mannstadt M.
    Endocrine; 2017 Jan; 55(1):273-282. PubMed ID: 27734257
    [Abstract] [Full Text] [Related]

  • 5. Pharmacokinetics and pharmacodynamics of subcutaneous recombinant parathyroid hormone (1-84) in patients with hypoparathyroidism: an open-label, single-dose, phase I study.
    Clarke BL, Kay Berg J, Fox J, Cyran JA, Lagast H.
    Clin Ther; 2014 May; 36(5):722-36. PubMed ID: 24802860
    [Abstract] [Full Text] [Related]

  • 6. Therapy of Hypoparathyroidism With rhPTH(1-84): A Prospective, 8-Year Investigation of Efficacy and Safety.
    Tay YD, Tabacco G, Cusano NE, Williams J, Omeragic B, Majeed R, Gomez Almonte M, Bilezikian JP, Rubin MR.
    J Clin Endocrinol Metab; 2019 Nov 01; 104(11):5601-5610. PubMed ID: 31310310
    [Abstract] [Full Text] [Related]

  • 7. The PARADIGHM (physicians advancing disease knowledge in hypoparathyroidism) registry for patients with chronic hypoparathyroidism: study protocol and interim baseline patient characteristics.
    Gittoes N, Rejnmark L, Ing SW, Brandi ML, Björnsdottir S, Hahner S, Hofbauer LC, Houillier P, Khan AA, Levine MA, Mannstadt M, Shoback DM, Vokes TJ, Zhang P, Marelli C, Germak J, Clarke BL.
    BMC Endocr Disord; 2021 Nov 20; 21(1):232. PubMed ID: 34801015
    [Abstract] [Full Text] [Related]

  • 8. Safety and Efficacy of 5 Years of Treatment With Recombinant Human Parathyroid Hormone in Adults With Hypoparathyroidism.
    Mannstadt M, Clarke BL, Bilezikian JP, Bone H, Denham D, Levine MA, Peacock M, Rothman J, Shoback DM, Warren ML, Watts NB, Lee HM, Sherry N, Vokes TJ.
    J Clin Endocrinol Metab; 2019 Nov 01; 104(11):5136-5147. PubMed ID: 31369089
    [Abstract] [Full Text] [Related]

  • 9. Therapy of Hypoparathyroidism With PTH(1-84): A Prospective Six Year Investigation of Efficacy and Safety.
    Rubin MR, Cusano NE, Fan WW, Delgado Y, Zhang C, Costa AG, Cremers S, Dworakowski E, Bilezikian JP.
    J Clin Endocrinol Metab; 2016 Jul 01; 101(7):2742-50. PubMed ID: 27144931
    [Abstract] [Full Text] [Related]

  • 10. Recombinant human parathyroid hormone (1-84) replacement therapy in a child with hypoparathyroidism.
    Laurer E, Grünberger J, Naidoo U, Lanzersdorfer R, Wimleitner M, Tischlinger K, Högler W.
    Bone; 2021 Mar 01; 144():115834. PubMed ID: 33359892
    [Abstract] [Full Text] [Related]

  • 11. Multicenter retro-prospective observational study on chronic hypoparathyroidism and rhPTH (1-84) treatment.
    Marcucci G, Beccuti G, Carosi G, Cetani F, Cianferotti L, Colao AM, Di Somma C, Duradoni M, Elefante A, Ghizzoni L, Giusti M, Lania AG, Lavezzi E, Madeo B, Mantovani G, Marcocci C, Masi L, Parri S, Pigliaru F, Santonati A, Spada A, Vera L, Brandi ML.
    J Endocrinol Invest; 2022 Sep 01; 45(9):1653-1662. PubMed ID: 35460461
    [Abstract] [Full Text] [Related]

  • 12. Five-Year Estimated Glomerular Filtration Rate in Adults with Chronic Hypoparathyroidism Treated with rhPTH(1-84): A Retrospective Cohort Study.
    Ayodele O, Rejnmark L, Mu F, Lax A, Berman R, Swallow E, Gosmanova EO.
    Adv Ther; 2022 Nov 01; 39(11):5013-5024. PubMed ID: 36018496
    [Abstract] [Full Text] [Related]

  • 13. Open-label extension of a randomized trial investigating safety and efficacy of rhPTH(1-84) in hypoparathyroidism.
    Khan AA, Abbott LG, Ahmed I, Ayodele O, Gagnon C, Finkelman RD, Mezosi E, Rejnmark L, Takacs I, Yin S, Ing SW.
    JBMR Plus; 2024 Mar 01; 8(3):ziad010. PubMed ID: 38741607
    [Abstract] [Full Text] [Related]

  • 14. Recombinant Human Parathyroid Hormone (1-84): A Review in Hypoparathyroidism.
    Kim ES, Keating GM.
    Drugs; 2015 Jul 01; 75(11):1293-303. PubMed ID: 26177893
    [Abstract] [Full Text] [Related]

  • 15. Teriparatide (rhPTH 1-34) treatment in the pediatric age: long-term efficacy and safety data in a cohort with genetic hypoparathyroidism.
    Tuli G, Buganza R, Tessaris D, Einaudi S, Matarazzo P, de Sanctis L.
    Endocrine; 2020 Feb 01; 67(2):457-465. PubMed ID: 31705387
    [Abstract] [Full Text] [Related]

  • 16. Recombinant Human Parathyroid Hormone Effect on Health-Related Quality of Life in Adults With Chronic Hypoparathyroidism.
    Vokes TJ, Mannstadt M, Levine MA, Clarke BL, Lakatos P, Chen K, Piccolo R, Krasner A, Shoback DM, Bilezikian JP.
    J Clin Endocrinol Metab; 2018 Feb 01; 103(2):722-731. PubMed ID: 29099947
    [Abstract] [Full Text] [Related]

  • 17. Drug safety evaluation of parathyroid hormone for hypocalcemia in patients with hypoparathyroidism.
    Marcucci G, Della Pepa G, Brandi ML.
    Expert Opin Drug Saf; 2017 May 01; 16(5):617-625. PubMed ID: 28332412
    [Abstract] [Full Text] [Related]

  • 18. Five-year Estimated Glomerular Filtration Rate in Patients With Hypoparathyroidism Treated With and Without rhPTH(1-84).
    Chen KS, Gosmanova EO, Curhan GC, Ketteler M, Rubin M, Swallow E, Zhao J, Wang J, Sherry N, Krasner A, Bilezikian JP.
    J Clin Endocrinol Metab; 2020 Oct 01; 105(10):e3557-65. PubMed ID: 32738041
    [Abstract] [Full Text] [Related]

  • 19. Lower Risk of Cardiovascular Events in Adult Patients with Chronic Hypoparathyroidism Treated with rhPTH(1-84): A Retrospective Cohort Study.
    Ayodele O, Mu F, Berman R, Swallow E, Rejnmark L, Gosmanova EO, Kaul S.
    Adv Ther; 2022 Aug 01; 39(8):3845-3856. PubMed ID: 35696069
    [Abstract] [Full Text] [Related]

  • 20. Safety and Efficacy of Recombinant Human Parathyroid Hormone in Adults With Hypoparathyroidism Randomly Assigned to Receive Fixed 25-μg or 50-μg Daily Doses.
    Bilezikian JP, Clarke BL, Mannstadt M, Rothman J, Vokes T, Lee HM, Krasner A.
    Clin Ther; 2017 Oct 01; 39(10):2096-2102. PubMed ID: 28942334
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 7.